GlassScriptPhysician profile
Jamalah Munir
NPI 1235127259
$3,945.40
in general payments reported to CMS, 2019-2025
25 companies · $385 in 2025
The $385 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $325 · 2021: $454 · 2022: $779 · 2023: $626 · 2024: $1,108 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,118.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $768.32 | 2019-2024 | Impella |
| Abbott Laboratories | $748.65 | 2020-2024 | Dragonfly Opstar, Ensite, Tacticath Ablation Catheter, Sensor Enabled |
| Shockwave Medical, INC | $637.96 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $500.98 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $319.78 | 2020-2023 | Brilinta |
| Heartflow, INC. | $165.90 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $132.31 | 2020-2023 | Camzyos |
| Teleflex LLC | $127.97 | 2023 | Guideliner |
| Janssen Pharmaceuticals, INC | $73.78 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $48.76 | 2024 | Wegovy |
| Amarin Pharma, INC. | $46.69 | 2020-2021 | |
| Pfizer INC. | $40.43 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.81 | 2021 | |
| Esperion Therapeutics, INC. | $34.29 | 2020-2024 | Nexletol |
| Medtronic, INC. | $33.68 | 2023 | Micra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $27.37 | 2019-2020 | |
| Acist Medical Systems, INC. | $27.27 | 2022 | |
| Irhythm Technologies, INC. | $25.56 | 2019 | |
| Dova Pharmaceuticals | $22.54 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.29 | 2024 | Entyvio |
| Intercept Pharmaceuticals, INC. | $22.03 | 2022 | |
| Cardiovascular Systems INC. | $22.00 | 2019-2021 | |
| Penumbra, INC. | $19.53 | 2024 | Indigo System |
| Boston Scientific Corporation | $19.52 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.98 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamalah Munir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.